

Neoadjuvant treatment strategies for resectable pancreas cancer: a population-based analysis of the National Cancer Database

Radiotherapy and Oncology

143, 101-107

DOI: [10.1016/j.radonc.2020.01.007](https://doi.org/10.1016/j.radonc.2020.01.007)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. <i>Cancers</i> , 2020, 12, 1729.	1.7	26
2	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020, 123, 709-713.	2.9	20
3	Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Caseâ€“Control Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 3779-3788.	0.7	12
4	Surgical Treatment of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 1971.	1.7	20
6	Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. <i>Pancreatology</i> , 2021, 21, 1326-1341.	0.5	7
7	Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2021, 25, 179-191.	0.1	9
8	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8297-8308.	0.7	19
9	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
10	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 744161.	1.3	5
11	Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factorsâ€“Literature Review. <i>Medicina (Lithuania)</i> , 2022, 58, 756.	0.8	5
12	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 783-791.e1.	2.3	16
13	The Clinical Diagnostic Value of F-FDG PET/CT Combined with MRI in Pancreatic Cancer. <i>Contrast Media and Molecular Imaging</i> , 2022, 2022, 1-8.	0.4	0
14	Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 858-864.	0.6	2
15	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
16	Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 450-457.	0.6	1
17	Stereotactic body radiotherapy in pancreatic adenocarcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2024, 23, 14-19.	0.6	0